Loading clinical trials...
Loading clinical trials...
A Phase 1b, Randomized 2-Part Single-Center Study to Evaluate the PK and Safety of Multiple Ascending Oral Doses of PF614 and the Food Effect and BA/BE of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects
Conditions
Interventions
PF614
Naltrexone Hydrochloride
+1 more
Locations
1
United States
PRA Health Sciences-Early Development Services
Salt Lake City, Utah, United States
Start Date
September 8, 2021
Primary Completion Date
March 21, 2022
Completion Date
March 21, 2022
Last Updated
September 24, 2024
NCT00104325
NCT07118891
NCT01399385
NCT07295717
NCT03807401
NCT07271693
Lead Sponsor
Ensysce Biosciences
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions